These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16942126)

  • 1. Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.
    Palmer AJ; Currie CJ
    Pharmacoeconomics; 2006; 24(9):927-9; author reply 929-35. PubMed ID: 16942126
    [No Abstract]   [Full Text] [Related]  

  • 2. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
    Vondeling H; Iversen PB
    Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Home P; Bagust A; Taylor M; Ambery P; Mendes da Costa S
    Pharmacoeconomics; 2007; 25(9):801-2; author reply 802-5. PubMed ID: 17803338
    [No Abstract]   [Full Text] [Related]  

  • 6. [Status of glitazones in treatment of type 2 diabetes mellitus].
    Willeke A
    Internist (Berl); 2007 Jul; 48(7):749; author reply 749-50. PubMed ID: 17571246
    [No Abstract]   [Full Text] [Related]  

  • 7. Initiating antidiabetic drug therapy.
    Kostenbauder HB
    Clin Ther; 2008 May; 30(5):986; author reply 986-7. PubMed ID: 18555946
    [No Abstract]   [Full Text] [Related]  

  • 8. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
    Arnold N; McLean M; Chipps DR; Cheung NW
    Med J Aust; 2005 May; 182(9):494. PubMed ID: 15999431
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
    Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The benefit of pioglitazone in patients with diabetes mellitus type 2 and cardiovascular complications].
    Olsovský J
    Vnitr Lek; 2005 Dec; 51(12):1412. PubMed ID: 16430111
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K; Lübben G; Siebert U; Schramm W
    Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
    Schöffski O
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones.
    Mascitelli L; Pezzetta F
    N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
    [No Abstract]   [Full Text] [Related]  

  • 16. Determinants of prescribing patterns for type II diabetes at Primary Care Trust level.
    Lloyd DC; Scrivener G
    J Clin Pharm Ther; 2004 Aug; 29(4):389-94. PubMed ID: 15271107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes, thiazolidinediones: bad to the bone?
    Watts NB; D'Alessio DA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122
    [No Abstract]   [Full Text] [Related]  

  • 18. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glitazones--again].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies of diabetes, thiazolidinediones, and coronary heart disease.
    Walker AM; McAfee AT; Koro C
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1313-4; author reply 1314-6. PubMed ID: 18041104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.